Serum anti-p53 antibodies and prognosis of patients with small-cell lung cancer

Journal of the National Cancer Institute

Volumn 89, Issue 5, 1997, Pages 381-385

  Rosenfeld, Myrna R ^a,e   Malats, Núria ^b   Schramm, Laura ^a   Graus, Francesc ^c   Cardenal, Felipe ^c   Viñolas, Núria ^c   Rosell, Rafael ^d   Torà, Montserrat ^b   Real, Francisco X ^b   Posner, Jerome B ^a   Dalmau, Josep ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

^d HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^e Memorial Hospital for Cancer and Allied Diseases   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; PLATINUM DERIVATIVE; PROTEIN ANTIBODY; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG RESPONSE; EARLY CANCER; FEMALE; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; WEIGHT REDUCTION;

EID: 0031041102     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/89.5.381     Document Type: Article

References (32)

1. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991;351: 453-6.
2. Angelopoulou K, Diamandis EP, Sutherland DJ, Kellen JA, Bunting PS. Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int J Cancer 1994;58:480-7.
3. Caron de Fromentel C, May-Levin F, Mouriesse H, Lemerle J, Chandrasekaran K, May P. Presence of circulating antibodies against cellular protein p53 in a notable proportion of children with B-cell lymphoma. Int J Cancer 1987;39:185-9.
4. Marxsen J, Schmiegel W, Roder C, Harder R, Juhl H, Henne-Bruns D, et al. Detection of the anti-p53 antibody response in malignant and benign pancreatic disease. Br J Cancer 1994; 70:1031-4.
5. Winter SF, Minna JD, Johnson BE, Takahashi T, Gazdar AF, Carbone DP. Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res 1992;52:4168-74.
6. Davidoff AM, Iglehart JD, Marks JR. Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers. Proc Natl Acad Sci USA 1992;89:3439-42.
7. Labrecque S, Naor N, Thomson D, Matlashewski G. Analysis of the anti-p53 antibody response in cancer patients. Cancer Res 1993; 53:3468-71.
8. Crawford LV, Pim DC, Bulbrook RD. Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer 1982;30:403-8.
9. Peyrat JP, Bonneterre J, Lubin R, Vanlemmens L, Fournier J, Soussi T. Prognostic significance of circulating p53 antibodies in patients undergoing surgery for locoregional breast cancer. Lancet 1995;345:621-2.
10. Vojtesek B, Kovarik J, Dolezalova H, Nenutil R, Havlis P, Brentani RR, et al. Absence of p53 autoantibodies in a significant proportion of breast cancer patients. Br J Cancer 1995;71: 1253-6.
11. Abrams J, Doyle LA, Aisner J. Staging, prognostic factors, and special considerations in small cell lung cancer. Semin Oncol 1988;15: 261-77.
12. Ihde DC. Chemotherapy of lung cancer. N Engl J Med 1992;327:1434-41.
13. Rosenfeld MR, Meneses P, Dalmau J, Drobnjak M, Cordon-Cardo C, Kaplitt MG. Gene transfer of wild-type p53 results in restoration of tumor-suppressor function in a medulloblastoma cell line. Neurology 1995;45:1533-9.
14. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 1979;76:4350-4.
15. Armitage P, Berry G. Statistical methods in medical research. 2nd ed. Oxford: Blackwell Scientific, 1987.
16. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
17. Cox DR. Regression models and life tables. J Royal Stat Soc [B] 1972;34:187-220.
18. Kleinbaum DG, Kupper LL, Morgenstern H. Epidemiologic research. Principles and quantitative methods. Belmont: Lifetime Learning Publications, 1982.
19. Hosmer DW, Lemeshow S. Applied logistic regression. New York: John Wiley & Sons, 1989.
20. Souhami RL, Bradbury I, Geddes DM, Spiro SG, Harper PG, Tobias JS. Prognostic significance of laboratory parameters measured at diagnosis in small cell carcinoma of the lung. Cancer Res 1985;45:2878-82.
21. Spiegelman D, Maurer LH, Ware JH, Perry MC, Chahinian AP, Comis R, et al. Prognostic factors in small-cell carcinoma of the lung: an analysis of 1,521 patients. J Clin Oncol 1989; 7:344-54.
22. Lassen U, Osterlind K, Hansen M, Dombernowsky P, Bergman B, Hansen HH. Long-term survival in small-cell lung cancer: posttreatment characteristics in patients surviving 5 to 18+ years - an analysis of 1,714 consecutive patients. J Clin Oncol 1995;13:1215-20.
23. Green JA, Robertson LJ, Campbell IR, Jenkins J. Expression of the p53 gene and presence of serum autoantibodies in ovarian cancer: correlation with differentiation. Cancer Detect Prev 1995;19:151-5.
24. Rosenfeld MR, Schramm L, Dalmau J, Malkin MG. Prevalence of serum antibodies against the p53 tumor suppressor gene protein in patients with serum brain tumors. Neurology 1996;46:A362-A363.
25. Bourhis J, Lubin R, Roche B, Koscielny S, Bosq J, Dubois I, et al. Analyses of p53 serum antibodies in patients with head and neck squamous cell carcinoma. J Natl Cancer Inst 1996;88:1228-33.
26. Porzsolt F, Schmid M, Hoher D, Muche R, Gaus W, Montenarh M. Biologic relevance of auto-antibodies against p53 in patients with metastatic breast cancer. Onkologie 1994; 17:402-8.
27. Winter SF, Sekido Y, Minna JD, McIntire D, Johnson BE, Gazdar AF, et al. Antibodies against autologous tumor cell proteins in patients with small-cell lung cancer: association with improved survival. J Natl Cancer Inst 1993;85:2012-8.
28. de Wet M, Falkson G, Rapoport BL. Small cell lung cancer: analysis of factors influencing the response to treatment and survival. Oncology 1994;51:523-34.
29. Lubin R, Zalcman G, Bouchet L, Tredanel J, Legros Y, Cazals D, et al. Serum p53 antibodies as early markers of lung cancer. Nat Med 1995;1:701-2.
30. Trivers GE, DeBenedetti VM, Cawley HL, Caron G, Harrington AM, Bennett WP, et al. Anti-p53 antibodies in sera from patients with chronic obstructive pulmonary disease can pre-date a diagnosis of cancer. Clin Cancer Res 1996;2:1767-75.
31. Sorokine I, Ben-Mahrez K, Bracone A, Thierry D, Ishii S, Imamoto F, et al. Presence of circulating anti-c-myb oncogene product antibodies in human sera. Int J Cancer 1991;47:665-9.
32. Ben-Mahrez K, Sorokine I, Thierry D, Kawasumi T, Ishii S, Salmon R, et al. Circulating antibodies against c-myc oncogene product in sera of colorectal cancer patients. Int J Cancer 1990;46:35-8.